Interpretation of the "Expert consensus on the diagnosis and treatment of neonatal hyperammonemia"

Cheng CAI, Wu ZHAO, Hu HAO, Yuan SHI

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (5) : 515-523.

PDF(779 KB)
HTML
PDF(779 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (5) : 515-523. DOI: 10.7499/j.issn.1008-8830.2409151
GUIDELINE INTERPRETATION

Interpretation of the "Expert consensus on the diagnosis and treatment of neonatal hyperammonemia"

Author information +
History +

Abstract

This paper provides an interpretation of the "Expert consensus on the diagnosis and treatment of neonatal hyperammonemia" published in the May 2023 issue of the Chinese Journal of Contemporary Pediatrics. The interpretation focuses on key aspects such as the neurotoxicity of ammonia, classification of etiologies, diagnosis, nutritional management, and pharmacological treatment. The aim is to enhance awareness about ammonia testing and emphasize that treatment should not be delayed while awaiting etiological investigation, thereby advancing the diagnosis and treatment of neonatal hyperammonemia.

Key words

Hyperammonemia / Metabolic disease / Diagnosis / Treatment / Neonate

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Cheng CAI , Wu ZHAO , Hu HAO , et al. Interpretation of the "Expert consensus on the diagnosis and treatment of neonatal hyperammonemia"[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(5): 515-523 https://doi.org/10.7499/j.issn.1008-8830.2409151

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Ni B, Qin M, Zhao J, et al. A glance at transient hyperammonemia of the newborn: pathophysiology, diagnosis, and treatment: a review[J]. Medicine (Baltimore), 2022, 101(48): e31796. PMCID: PMC9726343. DOI: 10.1097/MD.0000000000031796 .
https://www.ncbi.nlm.nih.gov/pubmed/36482558
Cited in this article [39]
2
Raina R, Bedoyan JK, Lichter-Konecki U, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy[J]. Nat Rev Nephrol, 2020, 16(8): 471-482. PMCID: PMC7366888. DOI: 10.1038/s41581-020-0267-8 .
https://www.ncbi.nlm.nih.gov/pubmed/32269302
Cited in this article [19]
3
中华医学会儿科学分会新生儿学组青年委员会. 新生儿高氨血症诊断与治疗的专家共识[J].中国当代儿科杂志, 2023, 23(5): 437-447. DOI: 10.7499/j.issn.1008-8830.2302140 .
Cited in this article [3]
4
Dasarathy S, Mookerjee RP, Rackayova V, et al. Ammonia toxicity: from head to toe?[J]. Metab Brain Dis, 2017, 32(2): 529-538. PMCID: PMC8839071. DOI: 10.1007/s11011-016-9938-3 .
https://www.ncbi.nlm.nih.gov/pubmed/28012068
Cited in this article [5]
5
Ribas GS, Lopes FF, Deon M, et al. Hyperammonemia in inherited metabolic diseases[J]. Cell Mol Neurobiol, 2022, 42(8): 2593-2610. DOI: 10.1007/s10571-021 -01156-6 .
https://www.ncbi.nlm.nih.gov/pubmed/34665389
Cited in this article [4]
6
Hediger N, Landolt MA, Diez-Fernandez C, et al. The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders[J]. J Inherit Metab Dis, 2018, 41(4):689-698. DOI: 10.1007/s10545-018-0157-4 .
https://www.ncbi.nlm.nih.gov/pubmed/29520739
Cited in this article [7]
7
Ballard RA, Vinocur B, Reynolds JW, et al. Transient hyperammonemia of the preterm infant[J]. N Engl J Med, 1978, 299(17): 920-925. DOI: 10.1056/NEJM197810262991704 .
https://www.ncbi.nlm.nih.gov/pubmed/692597
Cited in this article [1]
8
Chapel-Crespo CC, Diaz GA, Oishi K. Efficacy of N-carbamoyl-L-glutamic acid for the treatment of inherited metabolic disorders[J]. Expert Rev Endocrinol Metab, 2016, 11(6): 467-473. PMCID: PMC6054484. DOI: 10.1080/17446651.2016.1239526 .
https://www.ncbi.nlm.nih.gov/pubmed/30034506
Cited in this article [3]
9
Md AN. Neonatal presentations of metabolic disorders[J]. Neoreviews, 2020, 21(10):e649-e662. DOI: 10.1542/neo.21-10-e649 .
https://www.ncbi.nlm.nih.gov/pubmed/33004558
Cited in this article [3]
10
Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia[J]. Adv Drug Deliv Rev, 2015, 90:55-68. DOI: 10.1016/j.addr.2015.04.009 .
https://www.ncbi.nlm.nih.gov/pubmed/25895618
Cited in this article [2]
11
Häberle J. Clinical and biochemical aspects of primary and secondary hyperammonemic disorders[J]. Arch Biochem Biophys, 2013, 536(2):101-108. DOI: 10.1016/j.abb.2013.04.009 .
https://www.ncbi.nlm.nih.gov/pubmed/23628343
Cited in this article [8]
12
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision[J]. J Inherit Metab Dis, 2019, 42(6): 1192-1230. DOI: 10.1002/jimd.12100 .
https://www.ncbi.nlm.nih.gov/pubmed/30982989
Cited in this article [31]
13
Burlina A, Gasperini S, la Marca G, et al. Long-term management of patients with mild urea cycle disorders identified through the newborn screening: an expert opinion for clinical practice[J]. Nutrients, 2023, 16(1):13. PMCID: PMC10780676. DOI: 10.3390/nu16010013 .
https://www.ncbi.nlm.nih.gov/pubmed/38201843
Cited in this article [3]
14
Summar ML, Mew NA. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders[J]. Pediatr Clin North Am, 2018, 65(2):231-246. DOI: 10.1016/j.pcl.2017.11.004 .
https://www.ncbi.nlm.nih.gov/pubmed/29502911
Cited in this article [3]
15
Guilder LL, Kronick JB. Organic acidemias[J]. Pediatr Rev, 2022, 43(3):123-134. DOI: 10.1542/pir.2020-000562 .
https://www.ncbi.nlm.nih.gov/pubmed/35229111
Cited in this article [3]
16
Häberle J, Chakrapani A, Ah Mew N, et al. Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories[J]. Orphanet J Rare Dis, 2018, 13(1): 219. PMCID: PMC6282273. DOI: 10.1186/s13023-018-0963-7 .
https://www.ncbi.nlm.nih.gov/pubmed/30522498
Cited in this article [3]
17
中华预防医学会出生缺陷预防与控制专业委员会新生儿筛查学组, 中华医学会儿科学分会临床营养学组, 中华医学会儿科学分会内分泌遗传代谢学组, 等. 单纯型甲基丙二酸尿症饮食治疗与营养管理专家共识[J]. 中国实用儿科杂志, 2018, 33(7): 481-486. DOI:10.19538/j.ek2018070601 .
Cited in this article [1]
18
Chakrapani A, Valayannopoulos V, Segarra NG, et al. Effect of carglumic acid with or without ammonia scavengers on hyperammonaemia in acute decompensation episodes of organic acidurias[J]. Orphanet J Rare Dis, 2018, 13(1):97. PMCID: PMC6011521. DOI: 10.1186/s13023-018-0840-4 .
https://www.ncbi.nlm.nih.gov/pubmed/29925411
Cited in this article [2]
19
Valayannopoulos V, Baruteau J, Delgado MB, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study[J]. Orphanet J Rare Dis, 2016, 11: 32. PMCID: PMC4815113. DOI: 10.1186/s13023-016-0406-2 .
https://www.ncbi.nlm.nih.gov/pubmed/27030250
Cited in this article [4]
20
Yap S, Lamireau D, Feillet F, et al. Real-world experience of carglumic acid for methylmalonic and propionic acidurias: an interim analysis of the multicentre observational PROTECT study[J]. Drugs R D, 2024, 24(1): 69-80. PMCID: PMC11035519. DOI: 10.1007/s40268-023-00449-z .
https://www.ncbi.nlm.nih.gov/pubmed/38198106
Cited in this article [2]
21
Ali R, Nagalli S. Hyperammonemia[M]//StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
Cited in this article [1]
22
Moore K, Dixit D, Wagner M. Topiramate-related hyperammonemia[J]. J Pharm Technol, 2016, 32(1):34-36. PMCID: PMC5998406. DOI: 10.1177/8755122515605849 .
https://www.ncbi.nlm.nih.gov/pubmed/34860953
Cited in this article [1]
23
Savy N, Brossier D, Brunel-Guitton C, et al. Acute pediatric hyperammonemia: current diagnosis and management strategies[J]. Hepat Med, 2018, 10: 105-115. PMCID: PMC6140721. DOI: 10.2147/HMER.S140711 .
https://www.ncbi.nlm.nih.gov/pubmed/30254497
Cited in this article [5]
24
Bélanger-Quintana A, Arrieta Blanco F, Barrio-Carreras D, et al. Recommendations for the diagnosis and therapeutic management of hyperammonaemia in paediatric and adult patients[J]. Nutrients, 2022, 14(13):2755. PMCID: PMC9269083. DOI: 10.3390/nu14132755 .
https://www.ncbi.nlm.nih.gov/pubmed/35807935
Cited in this article [2]
25
Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision[J]. J Inherit Metab Dis, 2021, 44(3):566-592. PMCID: PMC8252715. DOI: 10.1002/jimd.12370 .
https://www.ncbi.nlm.nih.gov/pubmed/33595124
Cited in this article [1]
26
中华人民共和国国家卫生健康委员会. 国家卫生健康委办公厅关于印发罕见病诊疗指南（2019年版）的通知: 国卫办医函〔2019〕198号[EB/OL]. (2019-02-27)[2025-01-11].
http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333.shtml
Cited in this article [2]
27
Longo N, Diaz GA, Lichter-Konecki U, et al. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders[J]. Mol Genet Metab, 2021, 132(1):19-26. PMCID: PMC8655853. DOI: 10.1016/j.ymgme.2020.12.002 .
https://www.ncbi.nlm.nih.gov/pubmed/33388234
Cited in this article [4]
28
Berry SA, Lichter-Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes[J]. Mol Genet Metab, 2014, 112(1):17-24. PMCID: PMC4382922. DOI: 10.1016/j.ymgme.2014.02.007 .
https://www.ncbi.nlm.nih.gov/pubmed/24630270
Cited in this article [2]
29
Diaz GA, Schulze A, Longo N, et al. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients[J]. Mol Genet Metab, 2019, 127(4): 336-345. DOI: 10.1016/j.ymgme.2019.07.004 .
https://www.ncbi.nlm.nih.gov/pubmed/31326288
Cited in this article [1]
30
Imbard A, Bouchereau J, Arnoux JB, et al. Citrulline in the management of patients with urea cycle disorders[J]. Orphanet J Rare Dis, 2023, 18(1): 207. PMCID: PMC10362745. DOI: 10.1186/s13023-023-02800-8 .
https://www.ncbi.nlm.nih.gov/pubmed/37480106
Cited in this article [1]
31
Vernon HJ, Manoli I. Milestones in treatments for inborn errors of metabolism: reflections on where chemistry and medicine meet[J]. Am J Med Genet A, 2021, 185(11):3350-3358. DOI: 10.1002/ajmg.a.62385 .
https://www.ncbi.nlm.nih.gov/pubmed/34165242
Cited in this article [1]
32
Burlina A, Bettocchi I, Biasucci G, et al. Long-term use of carglumic acid in methylmalonic aciduria, propionic aciduria and isovaleric aciduria in Italy: a qualitative survey[J]. Eur Rev Med Pharmacol Sci, 2022, 26(14): 5136-5143. DOI: 10.26355/eurrev_202207_29302 .
https://www.ncbi.nlm.nih.gov/pubmed/35916811
Cited in this article [2]
33
Baumgartner MR, Hörster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia[J]. Orphanet J Rare Dis, 2014, 9:130. PMCID: PMC4180313. DOI: 10.1186/s13023-014-0130-8 .
https://www.ncbi.nlm.nih.gov/pubmed/25205257
Cited in this article [1]
34
Ronco C, Garzotto F, Brendolan A, et al. Continuous renal replacement therapy in neonates and small infants: development and first-in-human use of a miniaturised machine (CARPEDIEM)[J]. Lancet, 2014, 383(9931):1807-1813. DOI: 10.1016/S0140-6736(14)60799-6 .
https://www.ncbi.nlm.nih.gov/pubmed/24856026
Cited in this article [2]
35
Goldstein SL, Vidal E, Ricci Z, et al. Survival of infants treated with CKRT: comparing adapted adult platforms with the Carpediem™[J]. Pediatr Nephrol, 2022, 37(3): 667-675. PMCID: PMC8376293. DOI: 10.1007/s00467-021-05180-y .
https://www.ncbi.nlm.nih.gov/pubmed/34414499
Cited in this article [1]

蔡成、赵武、郝虎负责文献检索和整理、共识解读及论文撰写；赵武、郝虎负责循证医学指导、指南解读、统计学指导；蔡成、史源负责论文设计、写作指导、共识解读、审阅、修改。

PDF(779 KB)
HTML

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉